Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer study.

CONTEXT The cardiac natriuretic peptides are involved in blood pressure regulation, and large cross-sectional studies have shown lower plasma levels of N-terminal pro-natriuretic peptide levels [N-terminal atrial natriuretic peptide (N-ANP) and N-terminal brain natriuretic peptide (N-BNP)] in patients with insulin resistance, obesity, and diabetes. OBJECTIVE In this study, we prospectively tested whether plasma levels of mid-regional ANP (MR-ANP) and N-BNP predict new-onset diabetes and long-term glucose progression. DESIGN, SETTING, AND PATIENTS MR-ANP and N-BNP were measured in 1828 nondiabetic individuals of the Malmö Diet and Cancer cohort (mean age 60 yr; 61% women) who subsequently underwent a follow-up exam including an oral glucose tolerance test after a median follow-up time of 16 yr. Logistic regression was used to adjust for covariates. RESULTS During follow-up, 301 subjects developed new-onset diabetes. After full multivariate adjustment, MR-ANP was significantly inversely associated with incident diabetes (OR = 0.85; 95% CI = 0.73-0.99; P = 0.034) but not N-BNP (OR = 0.92; 95% CI = 0.80-1.06; P = 0.262). In fully adjusted linear regression models, the progression of fasting glucose during follow-up was significantly inversely related to baseline levels of MR-ANP (P = 0.004) but not N-BNP (P = 0.129). Quartile analyses revealed that the overall association was mainly accounted for by excess risk of incident diabetes in subjects belonging to the lowest quartile of MR-ANP. After full adjustment, the odds ratio for incident diabetes in the bottom compared with the top quartile of MR-ANP was 1.65 (OR = 1.08-2.51, P = 0.019) and 1.43 (OR = 1.04-1.96, P = 0.027) compared with all other subjects. CONCLUSION Low plasma levels of MR-ANP predict development of future diabetes and glucose progression over time, suggesting a causal role of ANP deficiency in diabetes development.

[1]  Pedro Lozano Natriuretic peptides. , 2020, The Journal of the Arkansas Medical Society.

[2]  L. Groop,et al.  Plasma Copeptin and the Risk of Diabetes Mellitus , 2010, Circulation.

[3]  V. Salomaa,et al.  Thirty-One Novel Biomarkers as Predictors for Clinically Incident Diabetes , 2010, PloS one.

[4]  K. Nakao,et al.  Natriuretic Peptides/cGMP/cGMP-Dependent Protein Kinase Cascades Promote Muscle Mitochondrial Biogenesis and Prevent Obesity , 2009, Diabetes.

[5]  J. Struck,et al.  Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. , 2009, Journal of the American College of Cardiology.

[6]  D. Levy,et al.  Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure , 2009, Nature Genetics.

[7]  G. Berglund,et al.  Elevated Lp-PLA2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[8]  M. Volpe,et al.  Reduced levels of N-terminal-proatrial natriuretic peptide in hypertensive patients with metabolic syndrome and their relationship with left ventricular mass , 2007, Journal of hypertension.

[9]  D. Levy,et al.  Association of Plasma Natriuretic Peptide Levels With Metabolic Risk Factors in Ambulatory Individuals , 2007, Circulation.

[10]  P. Arner,et al.  Atrial natriuretic peptide inhibits the production of adipokines and cytokines linked to inflammation and insulin resistance in human subcutaneous adipose tissue , 2007, Diabetologia.

[11]  T. Jørgensen,et al.  N-Terminal Pro Brain Natriuretic Peptide Is Inversely Related to Metabolic Cardiovascular Risk Factors and the Metabolic Syndrome , 2005, Hypertension.

[12]  D. Siscovick,et al.  Cystatin C and the risk of death and cardiovascular events among elderly persons. , 2005, The New England journal of medicine.

[13]  N. Moustaid‐Moussa,et al.  Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. , 2005, Diabetes.

[14]  A. Quyyumi,et al.  Renin-Angiotensin System and Angiotensin Receptor Blockers in the Metabolic Syndrome , 2004, Circulation.

[15]  D. Fliser,et al.  Antiinflammatory Effects of Angiotensin II Subtype 1 Receptor Blockade in Hypertensive Patients With Microinflammation , 2004, Circulation.

[16]  J. Mair,et al.  Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performance of markers. , 2004, Clinical chemistry.

[17]  D. Levy,et al.  Impact of Obesity on Plasma Natriuretic Peptide Levels , 2004, Circulation.

[18]  D Ghigo,et al.  Insulin Stimulates Glucose Transport Via Nitric Oxide/Cyclic GMP Pathway in Human Vascular Smooth Muscle Cells , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[19]  S. Jacob,et al.  Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance , 2003, Diabetes, obesity & metabolism.

[20]  Arya M. Sharma,et al.  Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. , 2002, Diabetes.

[21]  L. Niskanen,et al.  Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. , 2001, Diabetes care.

[22]  J. Mair,et al.  Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[23]  R. Sarzani,et al.  Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients , 1997, Journal of Hypertension.

[24]  E. Verspohl,et al.  Atrial natriuretic peptide (ANP)-induced inhibition of glucagon secretion: Mechanism of action in isolated rat pancreatic islets , 1996, Peptides.

[25]  C. Kahn,et al.  Cross-talk between the insulin and angiotensin signaling systems. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  D. Harrison,et al.  Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. , 1996, The Journal of clinical investigation.

[27]  D. Garbers,et al.  Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide , 1995, Nature.

[28]  O. Smithies,et al.  Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension , 1995, Science.

[29]  T. Yandle,et al.  Biochemistry of natriuretic peptides , 1994, Journal of internal medicine.

[30]  Professor Göran Berglund The Malmö Diet and Cancer Study Design, biological bank and biomarker programme , 1993 .

[31]  P. Weidmann,et al.  Increase in Circulating Insulin Induced by Atrial Natriuretic Peptide in Normal Humans , 1986, Journal of cardiovascular pharmacology.

[32]  S. Yusuf,et al.  Effects of Telmisartan on Glucose Levels in People at HighRisk for Cardiovascular Disease but Free FromDiabetes The TRANSCEND study , 2011 .

[33]  F. Di Serio,et al.  Analytical evaluation of the Dade Behring Dimension RxL automated N-Terminal proBNP (NT-proBNP) method and comparison with the Roche Elecsys 2010 , 2005, Clinical chemistry and laboratory medicine.

[34]  J. Struck,et al.  Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. , 2004, Clinical chemistry.

[35]  E. Bonora,et al.  Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. , 2000, Diabetes care.

[36]  C. Berne,et al.  Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats , 1998, Diabetologia.

[37]  Minisymposium: The Malmö Diet and Cancer Study. Design, biological bank and biomarker programme. 23 October 1991, Malmo, Sweden. , 1993, Journal of Internal Medicine.

[38]  K. Hosoda,et al.  Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. , 1992, Endocrinology.